CURA stocks, 14 analysts have issued a “buy” rating Analysts are bullish on Curaleaf. Of the 15 analysts covering the stocks, 14 analysts have issued a “buy” rating, while the remaining one analyst has given a “hold” rating. The consensus price target stands at $25.16, representing a return potential of 27.4%.
Amid speculative trading fears, the cannabis sector witnessed a strong selloff over the last few weeks, with the benchmark index, the Horizons Marijuana Life Sciences Index ETF, trading around 38% lower from its recent highs. Amid the weakness in the cannabis sector, Curaleaf is currently trading over 15% lower from its 52-week high. So, investors should utilize this pullback to buy Curaleaf to earn superior returns this year.
https://www.fool.ca/2021/03/11/should-you-buy-curaleaf-holdings-cnsxcura-after-its-4th-quarter-performance/